Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of CKD-395 vs Co-administered Lobeglitazone and Metformin in Healthy Males
NCT02565368Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jul 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lobeglitazone + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the Last Measurable Concentration at 48 hours and Maximum Plasma Concentration at 48 hours. Started Jul 2015; status: completed.
02
Drugs
lobeglitazone + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02565368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02565368.